专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP2225252B1 C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES 有权
标题翻译： C2-C5-ALKYLIMIDAZOLBISPHOSPHONATE
公开(公告)号：EP2225252B1
公开(公告)日：2012-06-27
申请号：EP08854485.3
申请日：2008-11-26
申请人： Novartis AG
发明人： WEILER, Sven , WIDLER, Leo , RONDEAU, Jean-Michel , COTESTA, Simona , JAHNKE, Wolfgang
IPC分类号： C07F9/6506 , A61K31/663 , A61P19/00
CPC分类号： C07F9/65061
摘要： C2-C5-Alkyl-substituted [(imidazol-1 -yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula (I), wherein one of R1 and R2 is hydrogen and the other is C2-C5-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.

2. 发明公开

EP2094645A1 2-HYDROXY-1,3-DIAMINOPROPANE DERIVATIVES 审中-公开
标题翻译： 2-羟基-1,3-二氨基 - 衍生物
公开(公告)号：EP2094645A1
公开(公告)日：2009-09-02
申请号：EP07847275.0
申请日：2007-11-22
申请人： NOVARTIS AG
发明人： FREDERIKSEN, Mathias , LÜÖND, Rainer Martin , MCCARTHY, Clive , MOEBITZ, Henrik , RONDEAU, Jean-Michel , ROY, Bernard Lucien , RUEEGER, Heinrich
IPC分类号： C07C233/40 , C07D213/74 , C07D231/38 , C07D237/20 , C07D239/42 , C07D239/46 , C07D239/52 , C07D261/14 , C07D401/12 , C07D487/04 , A61K31/505 , A61K31/44 , A61K31/165 , A61P25/28
CPC分类号： C07D401/12 , C07C233/40 , C07C2601/02 , C07D213/74 , C07D231/38 , C07D237/20 , C07D239/42 , C07D239/47 , C07D239/52 , C07D261/14 , C07D487/04
摘要： The invention relates to novel cyclic compounds of the formula (I), in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
摘要翻译：本发明涉及式（I）的新型环状化合物，其游离碱形式或酸加成盐形式，用于其制备，用作药物和包含它们的药物。

3. 发明公开

EP2382223A1 PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS 审中-公开
标题翻译：苯基 - 咪唑 - 二膦酸酯化合物
公开(公告)号：EP2382223A1
公开(公告)日：2011-11-02
申请号：EP09806020.5
申请日：2009-12-21
申请人： Novartis AG
发明人： COTESTA, Simona , JAHNKE, Wolfgang , RONDEAU, Jean-Michel , WEILER, Sven , WIDLER, Leo
IPC分类号： C07F9/6506 , A61K31/663
CPC分类号： C07F9/65061
摘要： (Unsubstituted or substituted phenyl)-alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1- phosphono-ethyl]-phosρhonic, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are disclosed. The compounds are able to inhibit excessive or inappropriate bone resorption. The compounds are of the formula (I), wherein one of R
1 and R
2 are as defined in the specification, and can be in free form, in the form of an ester, and/or of a salt.
摘要翻译：（未取代的或取代的苯基） - 烷基取代的[（咪唑-1-基）-1-羟基-1-膦酰基乙基] - 膦酸，以及它们的制备方法或方法，它们在制备药物制剂中的用途，它们在治疗疾病中的用途，使用它们治疗疾病的方法，包含它们的药物制剂和/或用于治疗疾病的化合物。这些化合物能够抑制过度或不适当的骨吸收。所述化合物是式（I）的化合物，其中R 1和R 2中的一个如说明书中所定义，并且可以以游离形式，以酯和/或盐的形式存在。

4. 发明公开

EP2342173A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS 审中-公开
标题翻译： SALICYLSÄUREDERIVATE，BEI DENEN ES SICH UM INHIBITOREN DERFARNESYLPYROPHOSPHATSYNTHASEAKTIVITÄTHANDELT
公开(公告)号：EP2342173A1
公开(公告)日：2011-07-13
申请号：EP09741267.0
申请日：2009-10-12
申请人： Novartis AG
发明人： COTESTA, Simona , GLICKMAN, Joseph Fraser , JAHNKE, Wolfgang , MARZINZIK, Andreas , OFNER, Silvio , RONDEAU, Jean-Michel , ZOLLER, Thomas
IPC分类号： C07C65/21 , C07C229/64 , C07D207/06 , C07D207/08 , C07D209/08 , C07D211/22 , C07D213/74 , C07D231/38 , C07D295/10 , C07D307/14 , C07D319/08 , C07D333/20 , A61P43/00 , A61K31/192
CPC分类号： C07D207/26 , C07C65/24 , C07C229/64 , C07C233/54 , C07C255/58 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07C2601/18 , C07D207/09 , C07D207/327 , C07D209/18 , C07D211/22 , C07D211/58 , C07D213/36 , C07D213/64 , C07D213/74 , C07D231/38 , C07D243/08 , C07D295/155 , C07D295/185 , C07D307/14 , C07D307/54 , C07D307/79 , C07D317/60 , C07D319/18 , C07D333/20 , C07D333/60
摘要： The invention relates to the use of and mainly novel compounds of the formula (I) wherein the moieties are as defined in the description, which are useful as farnesyl pyrophosphate synthase modulators and e.g. in the treatment of proliferative diseases.
摘要翻译：本发明涉及主要使用和主要新颖的式I化合物，其中部分如说明书中所定义，其可用作法呢基焦磷酸合酶调节剂，在治疗增生性疾病。

5. 发明公开

EP2225252A1 C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES 有权
标题翻译： C2-C5烷基咪唑双膦酸盐
公开(公告)号：EP2225252A1
公开(公告)日：2010-09-08
申请号：EP08854485.3
申请日：2008-11-26
申请人： Novartis AG
发明人： WEILER, Sven , WIDLER, Leo , RONDEAU, Jean-Michel , COTESTA, Simona , JAHNKE, Wolfgang
IPC分类号： C07F9/6506 , A61K31/663 , A61P19/00
CPC分类号： C07F9/65061
摘要： C2-C5-Alkyl-substituted [(imidazol-1 -yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula (I), wherein one of R1 and R2 is hydrogen and the other is C2-C5-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.
摘要翻译： C 2 -C 5 - 烷基取代的[（咪唑-1-基）-1-羟基-1-膦酰基乙基]膦酸，以及其制备方法或方法，其在制备药物制剂中的用途，它们的用于治疗疾病，使用它们治疗疾病的方法，包含它们的药物制剂和/或用于治疗疾病的化合物。这些化合物能够抑制过度或不适当的骨吸收，并用于治疗由靶蛋白过度异戊二烯化引起的其他疾病，如Hutchinson-Gilford早衰综合征。所述化合物是式（I）的化合物，其中R 1和R 2中的一个是氢并且另一个是支链或非支链的C 2 -C 5 - 烷基，并且可以以酯的形式呈游离形式，和/或的盐。

6. 发明公开

EP1989194A1 CYCLIC SULFONES USEFUL AS BACE INHIBITORS 有权
标题翻译：循环砜打算用作BACE抑制剂适合...
公开(公告)号：EP1989194A1
公开(公告)日：2008-11-12
申请号：EP07712220.8
申请日：2007-02-14
申请人： NOVARTIS AG
发明人： RUEEGER, Heinrich , MCCARTHY, Clive , MOEBITZ, Henrik , RONDEAU, Jean-Michel , TINTELNOT-BLOMLEY, Marina
IPC分类号： C07D335/02
CPC分类号： C07D335/02 , C07D409/12 , C07D413/10 , C07D413/12 , C07D417/12
摘要： The invention relates to novel heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

7. 发明授权

EP1776142B1 IL-17 ANTAGONISTIC ANTIBODIES 有权转让
标题翻译：拮抗性抗体针对IL-17
公开(公告)号：EP1776142B1
公开(公告)日：2011-07-27
申请号：EP05770286.2
申请日：2005-08-04
申请人： Novartis AG , Novartis Pharma GmbH
发明人： DI PADOVA, Franco, E. , GRAM, Hermann , HOFSTETTER, Hans , JESCHKE, Margit , RONDEAU, Jean-Michel , VAN DEN BERG, Wim
IPC分类号： C07K16/24
CPC分类号： C07K16/244 , C07K2317/21 , C07K2317/55 , C07K2317/76 , C07K2317/92
摘要： An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.

8. 发明公开

EP2303857A1 CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS 审中-公开
标题翻译：含有氨基取代基的环状磺酸作为BACE抑制剂
公开(公告)号：EP2303857A1
公开(公告)日：2011-04-06
申请号：EP09780309.2
申请日：2009-07-08
申请人： Novartis AG
发明人： BRIARD, Emmanuelle , LUEOEND, Rainer, Martin , MACHAUER, Rainer , MOEBITZ, Henrik , ROGEL, Olivier , RONDEAU, Jean-Michel , RUEEGER, Heinrich , TINTELNOT-BLOMLEY, Marina , VEENSTRA, Siem, Jacob
IPC分类号： C07D335/02 , C07D409/12 , A61K31/382 , A61P25/28
CPC分类号： C07D335/02 , C07D409/10 , C07D409/12 , C07D413/12 , C07F7/0812
摘要： The invention relates to novel heterocyclic compounds of the formula (I); in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
摘要翻译：本发明涉及新的式（I）杂环化合物; 其中所有变量如说明书中所定义，游离形式或盐形式，它们的制备，它们作为药物的用途以及包含它们的药物。

9. 发明授权

EP1776142B9 IL-17 ANTAGONISTIC ANTIBODIES 有权转让
标题翻译：拮抗性抗体针对IL-17
公开(公告)号：EP1776142B9
公开(公告)日：2016-09-07
申请号：EP05770286.2
申请日：2005-08-04
申请人： Novartis AG , Novartis Pharma GmbH
发明人： DI PADOVA, Franco, E. , GRAM, Hermann , HOFSTETTER, Hans , JESCHKE, Margit , RONDEAU, Jean-Michel , VAN DEN BERG, Wim
IPC分类号： C07K16/24
CPC分类号： C07K16/244 , C07K2317/21 , C07K2317/55 , C07K2317/76 , C07K2317/92

10. 发明公开

EP1776142A1 IL-17 ANTAGONISTIC ANTIBODIES 有权转让
标题翻译： ANTAGONISTISCHEANTIKÖRPERGEGEN IL-17
公开(公告)号：EP1776142A1
公开(公告)日：2007-04-25
申请号：EP05770286.2
申请日：2005-08-04
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
发明人： DI PADOVA, Franco, E. , GRAM, Hermann , HOFSTETTER, Hans , JESCHKE, Margit , RONDEAU, Jean-Michel , VAN DEN BERG, Wim
IPC分类号： A61K39/395 , A61P29/00 , C07K16/24
CPC分类号： C07K16/244 , C07K2317/21 , C07K2317/55 , C07K2317/76 , C07K2317/92
摘要： An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.
摘要翻译：提供IL-17结合分子，特别是人IL-17的抗体，更优选IL-17的人抗体，其中重链和轻链的高变区具有如我们所定义的氨基酸序列治疗IL-17介导的疾病或病症，例如类风湿关节炎。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式